ZDd Shows Strong MRD-Negative CR in RRMM; Camzyos PDUFA Looms
BMY sits 48% above its 52-week low of $42.52.
Summary
Phase 3 EXCALIBER-RRMM interim data show ZDd (iberdomide+daratumumab+dex) achieved MRD-negative complete response in 41.1% of patients vs 20.7% for DVd, with ORR of 88.9% vs 76.1%, though neutropenia was higher. This strengthens the case for ZDd in relapsed/refractory multiple myeloma, a key growth area. Separately, the FDA decision on Camzyos label expansion to ages 12-17 is due Sept. 30, with adolescent safety mirroring adults. The company is also lobbying to retain China licensing rights after large 2026 upfront payments, including one over $600M. These developments follow the recent accelerated approval of iberdomide (Zenbexus) and the Zola-Cel program pause, highlighting both pipeline momentum and regulatory risk.
At the time of this announcement, BMY was trading at $62.85 on NYSE in the Life Sciences sector, with a market capitalization of approximately $128.4B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.